Potential New Treatment for Metastatic Lung Cancer
Trial Objectives
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet current treatment options are limited. In fact, the standard treatment for metastatic NSCLC has a low 5-year survival rate.
Researchers want to know if an investigational drug called SAR408701 is better than docetaxel, a chemotherapy drug already approved to treat non-small cell lung cancer (NSCLC) patients with CEACAM 5 positive tumors. The goal of this study is to determine if SAR408701 improves survival rate for NSCLC patients.
Over the course of the study, participants will have 1-2 clinic visits each month where they will receive physical exams to evaluate their response to either SAR408701 or docetaxel and monitor disease progression. Data gathered will allow researchers to track improvements in disease response, quality of life and overall symptoms to determine the effectiveness of the new drug.
Who Can Participate
Adults aged 18 years and older being treated at National Jewish Health for non-small cell lung cancer, who have progressive disease during or after at least 2 cycles of platinum-based chemotherapy and an immune checkpoint inhibitor.
Age: 18+ Gender: Any
Estimated Time Commitment
1 year
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Sanofi
Principal Investigators
Laurie L. Carr, MD